Eli Lilly Partners with NVIDIA to Create a Groundbreaking AI Supercomputer
New AI capabilities will assist scientists in discovering and optimizing novel therapeutic molecules. This partnership promises to enhance various applications including manufacturing, medical imaging, and enterprise AI solutions.
Eli Lilly and Company (NYSE: LLY) has announced an exciting new collaboration with NVIDIA to establish the most potent supercomputer operated by a pharmaceutical firm. This state-of-the-art supercomputer will function as an "AI factory," streamlining the entire process of AI development—from data collection and model training to precise tuning and large-scale inferences.
Diogo Rau, the executive vice president and chief information and digital officer at Lilly, highlighted the company's commitment to leveraging advanced technologies alongside scientific excellence. He stated, "Lilly has a rich 150-year history, and our vast repository of data represents a significant asset. With custom-built AI models, we aim to set a new standard for scientific inquiry, accelerating innovation to bring medicines to patients more rapidly than ever before."
This supercomputer will be the world's first NVIDIA DGX SuperPOD integrated with DGX B300 systems, featuring over 1,000 B300 GPUs interconnected through a unified high-speed network. This cutting-edge technology enables seamless communication between GPUs and associated storage systems.
Enhancing Drug Discovery and Development Efficiency
The integration of the supercomputer and AI factory fosters quick learning and frequent updates in research efforts. With this advancement, scientists can train models based on millions of experiments, significantly enhancing the breadth and complexity of drug discovery initiatives. Many proprietary AI models will be accessible on Lilly TuneLab, an innovative federated AI/ML drug discovery platform aimed at democratizing access to advanced research tools across the biopharmaceutical landscape. TuneLab will regularly update its offerings, incorporating workflows that utilize selected NVIDIA Clara open-source models.
Moreover, Lilly plans to utilize the supercomputer to expedite the drug development process, ensuring that life-saving medicines reach the market more swiftly. New AI-driven agents will aid researchers in reasoning, planning, and collaborating seamlessly across digital and physical platforms. Enhanced medical imaging technologies will provide scientists with greater clarity on disease progression and facilitate the development of new biomarkers for personalized treatment approaches. Furthermore, digital twin technologies combined with NVIDIA's robotics will optimize manufacturing processes, enhancing efficiency and minimizing downtime.
Embracing AI as a Collaborative Force in Medicine
Kimberly Powell, vice president of health care at NVIDIA, expressed her enthusiasm about the impact of this partnership, stating, "The AI industrial revolution is poised to radically reshape medicine and our understanding of biological processes. State-of-the-art AI factories are changing the landscape of scientific discovery, moving beyond traditional trial-and-error methodologies to a more intentional approach to medicine design. With its rich heritage in science and innovation, Lilly is well-positioned as a leader in this transformative medical era."
Thomas Fuchs, Lilly's senior vice president and chief AI officer, underscored the shift in their approach to technology. "We are redefining the role of AI from a mere tool to a genuine scientific collaborator. By embedding intelligence at all levels of our workflows, we’re pioneering a new enterprise model that learns and adapts with every data input. Our goal is to deepen our comprehension of diseases and convert that knowledge into meaningful advancements, benefiting both patients and the broader life sciences community."
Commitment to Sustainable Operations
In line with Lilly's sustainability objectives, which include achieving carbon neutrality by 2030, the supercomputer will operate entirely on renewable energy sourced from Lilly's facilities. Additionally, it will utilize the existing chilled water systems for efficient liquid cooling.
Lilly will be presenting valuable insights on "Enterprise-Scale AI for Drug Discovery: Strategy, Infrastructure and Outcomes" today at NVIDIA's influential AI conference, GTC. This presentation will shed light on the promising future of AI in pharmaceuticals.
About Eli Lilly and Company
Eli Lilly is dedicated to transforming science into healing to improve lives globally. With nearly 150 years of history, Lilly's impactful medicines aid millions worldwide. By leveraging biotechnology, advanced chemistry, and genetic medicine, the company is committed to addressing critical health issues. These include revolutionizing diabetes care, tackling obesity consequences, advancing Alzheimer’s disease research, managing immune disorders, and turning challenging cancers into treatable conditions. Through rigorous innovation and extensive clinical trials, Lilly strives to ensure their medicines remain accessible and affordable for all patients.
Frequently Asked Questions
What is the significance of the partnership between Eli Lilly and NVIDIA?
This collaboration aims to develop a state-of-the-art AI supercomputer that will enhance drug discovery processes, improve development efficiency, and optimize healthcare solutions.
How does the new supercomputer benefit drug development?
The supercomputer provides a sophisticated platform for quicker data processing, enabling researchers to test millions of experiments and refine drug discovery efforts.
In what ways is artificial intelligence changing the pharmaceutical industry?
AI is transitioning from a tool to a collaborative partner in research, allowing for deeper insights into diseases and more strategic drug design and development processes.
What measures is Lilly taking to ensure sustainability in its operations?
Lilly's supercomputer will operate on 100% renewable energy and utilize efficient liquid cooling systems to support the company’s carbon neutrality goal by 2030.
Where can I find more information about Eli Lilly's innovations?
For more insights, visit Lilly's official website or follow their social media platforms to stay updated on their research and developments.
